乙肝病毒感染的携带者、肝硬化及肝癌患者红细胞CD58分子水平差异研究

The differences research of the carriers, cirrhosis, liver cancer patients of hepatitis B virus infections and the molecular level of CD58

目的:比较乙肝病毒感染的正常携带者、肝硬化及肝癌患者红细胞CD58分子水平是否存在差异,以探讨CD58可否作为判断病情的一个标志。方法:分别抽取乙肝携带者、肝硬化及肝癌的全血,测定红细胞CD58分子的表达情况,以正常人作为对照组,比较各组间差异。结果:三组患者红细胞CD58分子数量的表达均显著低于正常对照组,差异有显著性(P<0.05);肝癌组与其他两组相比较,红细胞CD58分子数量亦显著降低(P<0.05)。但乙肝携带者组与肝硬化组的红细胞CD58分子数量的表达无显著性差异(P>0.05)。结论:CD58是判断乙肝病毒感染发展的一个较好指标。

Objective： Comparison of the carriers, cirrhosis and liver cancer patients of hepatitis B virus infections with CD58 on the molecular level, to discuss the Possibility of the CD58 as an indicator of development of the illness.Methods：Normal, The patients of Hepatitis B carriers, liver cirrhosis, and liver cancer were divided into 4 groups; their expression level of red cells＇ CD58 and the difference among the groups were detected.Results：There were differences of red cells＇ CD58 between 3 groups of patients and the normal group. The level red cells＇ CD58 of the liver cancer group was significantly lower than the other patients groups. But there was no significantly difference between the carriers and liver cirrhosis group.Conclusion： The level of red cells＇ CD58 is a good indicator to judge the development of the illness.